Abstract The purpose of this study was to assess the frequency of blood stream infections (BSIs) during neutropenia in different cycles of intensive chemotherapy treatment in acute myeloid leukemia (AML). The register data of 327 consecutive patients aged 16-66 years having de novo AML between September 1992 and December 2001 were prospectively gathered in five Finnish tertiary care leukemia centers. The patients had not received fluoroquinolone prophylaxis. Reported BSI rates were compared during neutropenia in four chemotherapy treatment cycles (C). There were 956 treatment episodes, with 456 (47.7%) positive blood cultures. BSI was monomicrobial in 327 episodes (71.7%) and polymicrobial in 129 (28.3%). The overall incidence rate (per 1,000 hospital days) for BSI was 13.2, varying from 6.8 in CI after idarubicin, conventional-dose cytarabine, and thioguanine to 15.6 in CII, 15.8 in CIII, and 17.6 in CIV. The distribution of monomicrobial gram-positive BSIs was as follows: CI, 71.7%; CII, 62.8%; CIII, 53.3%; CIV, 36.6%; and CI-IV together, 43.2%. The most common finding in the four different cycles was coagulase-negative staphylococci (38.3 to 30.6%). Viridans group streptococci were most commonly observed (in 20.4% of positive blood cultures) during CII after high-dose cytarabine and idarubicin treatments. The distribution of monomicrobial gramnegative BSIs was as follows: CI, 21.7%; CII, 36.3%; CIII, 45.7%; CIV, 46.9%; and CI-IV together, 37.9%. A great variation of incidence and types of microorganisms between AML chemotherapy cycles was found. It would be more reasonable to analyze chemotherapy cyclebased BSI results rather than the overall results.
Introduction
As early as 1960s, the importance of severe gram-negative bacterial blood stream infections (BSIs) during intensive chemotherapy of acute myeloid leukemia (AML) was identified [1] . In the 1970s, empirical treatment protocols were introduced to treat BSIs caused by gram-negative microorganisms in neutropenic fever patients [2] . During the next two decades, the causes of BSIs shifted from gramnegative rods to gram-positive cocci [3] [4] [5] [6] [7] [8] [9] . The most important reason for this change has been explained to be due to the use of antibiotic prophylaxis during periods of neutropenia in AML patients. Interestingly, the newest results suggest that the proportion of gram-negative infections is, once again, increasing [10] .
According to the knowledge of the authors, little attention has been paid to BSI rate during different chemotherapy cycles. When the febrile episodes of the so called SIGNIFICANT study [11] were later evaluated, it was found that, during the chemotherapy of solid tumors and lymphomas, the risk of a febrile episode, as a sign of possible BSI and an indication for empirical antibiotic treatment, was highest during the first treatment cycle, especially in testicular and small-cell lung cancers [12] . It was also noted that, if the patient had a febrile episode during the first chemotherapy cycle, he or she would have an increased risk of a febrile episode during the subsequent cycles [12] .
In solid tumors and lymphomas, patients receive repeated cycles of the same chemotherapeutics, whereas in AML, different chemotherapeutics are administrated in consecutive cycles in order to achieve a favorable outcome. As has been seen earlier in a small, single-center study, during AML treatment with an idarubicin, conventionaldose cytarabine, and thioguanine schedule, the BSI rate was lower than after other regimens [13] , whereas high-dose cytarabine treatment was associated with a high BSI rate. The present study was based on the nationwide AML-92 register data collected by the Finnish Leukemia Group [14] , in which 327 AML patients with 956 chemotherapy episodes were included for the evaluation of BSI rates. None of the patients had received any antibiotic prophylaxis during chemotherapy-induced neutropenia, which allowed us to observe the real BSI results in four consecutive chemotherapeutic cycles.
Materials and methods

Background
The study protocol and hematological results of this nationwide study population of 327 consecutive intensive chemotherapy-treated patients, of whom 82% experienced complete remission, has earlier been published elsewhere [14] .
Study design
The study protocol is briefly explained as follows (for a more extensive description, see [14] ). To be included, the patient had to have de novo AML diagnosed by standard cytological criteria according to the French-AmericanBritish (FAB) classification [15] , and be between 16 and 65 years old. The study protocol was approved by the ethical committees of all five participating centers. Moreover, the National Agency for Medicines scrutinized the protocol before the beginning of the study. All patients provided informed consent. During the first induction course, the chemotherapeutics used were idarubicin, conventional-dose cytarabine, and thioguanine. The second course, which was either the first postremission or second induction course, included high-dose cytarabine and idarubicin. The third course included etoposide, high-dose cytarabine, and mitoxantrone, and the fourth course amsacrine and high-dose cytarabine. The use of supportive treatments (i.e., growth factors, antibiotics, alimentation, and blood products) were administered according to the policies of each of the five hematological university centers. All patients had a central venous access. The infections were treated according to generally accepted guidelines [16, 17] . The patients did not receive any antibiotic prophylaxis during chemotherapy-induced neutropenia. For this study, the following information was used from the prospectively gathered register data of the AML patients recruited for the original study between September 1992 and December 2001: age at the time of diagnosis, sex, treatment faculty, FAB classification of AML, whether or not the patient had an infection at the time of AML diagnosis, and whether or not the patient had a positive blood culture (in ten episodes, data was missing). Moreover, the duration of hospital stays, neutropenia (days when the absolute neutrophil count was less than 500/µL), febrile days (body temperature ≥38°C), peak C-reactive protein (CRP) level (mg/L), and outcome of the patients were analyzed. Furthermore, gastrointestinal toxicity and the severity of infection categorized according to the WHO criteria was recorded in each episode [18] .
Microbiological methods
Blood was cultured at participating hospitals using automated continuous-monitoring blood culture systems (CMBCS): in two centers with BacT/Alert™ (bioMérieux Inc., Hazelwood, MS) and in three centers with Bactec 9240™ (BD Diagnostics, Diagnostic Systems, Sparks, MD).
The microorganisms were identified by standard microbiological methods based on growth conditions and appearance on solid media, fermentation of sugars and other organic compounds, as well as the use of commercial kits. Whether blood culture findings were true or contaminant was accepted by attending physicians, if more than one microorganism was recovered from the blood cultures of a patient during a chemotherapy cycle, the episode was defined as polymicrobial.
Statistical analysis
The summary measurements for continuous and ordinal variables are expressed as medians along with the 25th and 75th percentiles, unless otherwise stated. Fisher's exact test was used to analyze simple categorical data. The generalized linear mixed model approach was utilized for the comparison of the presence of positive BSI and toxicity in different chemotherapy cycles and the linear mixed model approach was used when comparing continuous variables (maximum CRP, duration of neutropenia, length of hospital stay, and duration of fever in days) between chemotherapy cycles. Both mixed-model approaches take into account that measurements are repeatedly taken from the same subjects and these within-subject measurements are not independent [19] . Furthermore, both methods use all of the data available, i.e., subjects with missing information are not dropped out from analyses. Incidence rates (per 1,000 hospital days or 1,000 neutropenic days) with 95% confidence intervals were calculated. If the number of hospital days or neutropenic days was missing, it was replaced by the cycle average. Statistical analysis was performed using the SPSS version 14.0 (SPSS Inc., Chicago, IL) and SAS version 9.1.3 (SAS Institute Inc., Cary, NC) statistical software packages.
Results
The study population included 327 AML patients and their most common FAB types were M2 with 32.1%, M1 with 23.9%, and M4 with 23.9%. There were 166 men and 161 women. Their median age was 47.7 years, with a range from 16 to 66 years of age. More detailed hematological results are presented elsewhere [14] . WHO grade IV infections with signs of organ failure were observed among 22 patients in cycle I (6.7%), 12 patients in cycle II (4.1%), 13 patients in cycle III (6.1%), and 9 patients in cycle IV (7.4%).
During the study period, there were 40 deaths (12.2%), of which 35 (87.5%) were due to infection. Twelve patients died due to infection during cycle I. Five of these deaths were due to BSIs. Of the 14 patients who died due to infection in cycle II, ten were treated with the second induction treatment for active disease. Seven of them had BSI. Only four patients treated with consolidation treatment in cycle II died because of infection. One of those infections was BSI. In cycle III, five deaths were due to infections, of which three were BSIs. In cycle IV, four patients died due to infection, with two BSIs among them.
In total, there were 956 treatment episodes with 456 positive blood cultures, constituting a rate of 47.7% of BSI. The overall incidence rate (per 1,000 hospital days) for BSI was 13.2 (95% confidence interval 12.0 to 14.5). When the cycles were compared, the median peak CRP level did not differ between the cycles, but the duration of febrile days was longest during the first cycle ( Table 1 ). The length of hospital stay and the incidence rate for BSI per 1,000 patient days or per 1,000 neutropenia days were clearly higher in cycles II, III, and IV than in cycle I ( Table 1 ). The odds ratio for BSI (compared to cycle I) was 5.8, 5.5, and 4.8 in cycles II, III, and IV, respectively (p<0.001, in all) ( Table 1) . Severe gastrointestinal toxicity (WHO grade III and IV) was highest during cycle I and decreased significantly in successive cycles, the odds ratios compared to cycle I being 0.65 in cycle II (p=0.041), 0.43 in cycle III (p<0.001), and 0.33 in cycle IV (p<0.001) ( Table 1 , Fig. 1 ).
During the first chemotherapy cycle, the number of BSIs was slightly higher if the patients did not have infections at the time of AML diagnosis (25.6%) than those patients having infections (19.3%, p=0.17; Fig. 2 ). During the second cycle, the BSI rate was still slightly higher in the patients who had already achieved remission (64.6%) than among those who received the second induction course of chemotherapy (53.6%, p = 0.11; Fig. 2 ). On the other hand, no difference in the number of febrile or neutropenic days, in the amount of grade 3 and 4 gastrointestinal toxicity, peak CRP values, or recovery of individual microbial strains was found between those patients with active disease and those in remission in the second cycle.
There was a great inter-cycle variation among positive blood cultures (from 23.3 to 61.6%), as well as for monomicrobial BSIs (from 62.2 to 83.3%) and for polymicrobial BSIs (from 16.7 to 37.2%). In monomicrobial BSIs, the proportion of gram-positive microorganisms decreased from cycle I (71.7%) to cycle IV (36.6%), whereas the change was in the opposite direction among gram-negatives, from 21.7% in cycle I to 46.9% in cycle IV ( Table 2 ). The most common gram-positive microorganisms in monomicrobial BSIs were coagulase-negative staphylococci (CoNS) and viridans group streptococci; the latter was most frequently detected during cycle II. The most common gram-negative microorganisms were E. coli (in cycles III and IV) and Klebsiella species (in cycles II and III). Anaerobic microorganisms were seen only in cycle I and some yeasts in cycles I-III (Table 2) .
Most polymicrobial BSIs contained two microorganisms ( Table 3 ). The most common combination included both gram-positive and gram-negative microorganisms in each cycle (41.8 to 64.3%). Although there was, once again, great variability between the cycles, the proportion of gramnegative microorganisms was always higher than 50% (from 52.3 to 82.1%).
When the BSI results obtained by two different automated blood systems were compared, there was no statistical difference between them concerning the cycles or individual microorganisms (data not shown).
Discussion
Our results show that, during the chemotherapy courses of adult AML patients, the BSI rate and yielded microorganisms vary greatly from cycle to cycle, probably reflecting the tendency of different chemotherapeutics to predispose patients to infections. Thus, the BSI results in AML should be evaluated based on cycles rather than on the overall results. Our study has several strengths. It was a prospective multicenter study with a large homogenous study population of 327 adult de novo AML patients treated according to the same schedule of chemotherapeutic protocol [14] . The patients had not received any prophylactic antibiotics for neutropenia, which allowed us to study the real influence of different chemotherapeutic cycles on BSI rates during neutropenia. Our statistical approach with linear and generalized linear mixed models took into account that the same subjects were evaluated repeatedly, i.e., the measurements of the same patients are not independent. On the other hand, our register data did not include the detection day of BSI from the onset of neutropenia. The other weakness of this study was that the gathered data did not include the resistance patterns of detected microorganisms or systematic information regarding the mucositis of the oral cavity of the study subjects. CoNS, coagulase-negative staphylococci; VGS, viridans group streptococci Among gram-positives and gram-negatives, only the three most common microbes are mentioned, and among gram-negatives, also the presence of Pseudomonas Our BSI proportion of 47.7% is higher than has been thus far reported; the figures in other studies have varied from 10 to 38.8% [11, [20] [21] [22] [23] [24] [25] . The crucial questions from the point of view of BSI frequency are study population (only leukemia patients or also patients with solid tumor and lymphomas) and whether the patients had received antibiotic prophylaxis during neutropenia. For example, in a large multicenter study with solid tumors and lymphomas, the BSI rate was 6.2% in the levofloxacin group and 7.9% in the placebo group [11] . In another multicenter study of patients having acute leukemia and a duration of neutropenia of at least 7 days, the BSI rate was 20.6% in the levofloxacin group and 38.8% in the placebo group [21] . In our study, the median duration of neutropenia was more than three weeks in each cycle, which is a well-known and real risk of higher BSI rate [1] . In one of our centers, the BSI rate during neutropenia among AML patients increased from 21 to 40% when a manual blood culture system was replaced by a CMBCS [26] . Taken together, we consider that our BSI rate is realistic and, moreover, our BSI incidence rate of 13.2 per 1,000 patient days is rather near to the corresponding figure of 10.2 published previously [27] .
When the BSI results were analyzed separately in each cycle, the recovery of microorganisms during the first chemotherapy-induced neutropenia was clearly lower than in other cycles. This phenomenon was relevant when the incidence rate per 1,000 patient days or per 1,000 neutropenia days was also calculated. Our result was rather surprising when gastrointestinal toxicity (WHO grades III and IV) was taken into account. High-dose cytarabine is well-known for its gastrointestinal toxicity. In the present data, the toxicity was highest in the first cycle. It should have been lowest because the dose of cytarabine in the first cycle was conventional rather than high, as in the later cycles. As gastrointestinal toxicity was highest in the first cycle, the recovery of microorganisms should also have been highest, but that was not the case. We can give no exact explanation for these observations, but we can speculate that leukemia, per se, may have something to do with these findings. In the first cycle, all patients had active disease. Altered intestinal permeability and the absorption of sugars have been demonstrated in patients with AML, even without treatment [28, 29] . Another explanation to our surprising findings may be that measuring toxicity by the WHO method is not sensitive enough for identifying these kinds of changes in the gastrointestinal tract. On the other hand, in the present data, 63% of deaths due to infection occurred in patients receiving induction treatment. It seems that the outcome of infections is worse among AML patients with active disease than among those who have achieved remission.
During the last few decades, there has been a clear shift from gram-negative BSIs to gram-positive BSIs in neutropenic infections, which has been suggested to be due to the increased use of intravascular devices, fluoroquinolone prophylaxis, and chemotherapy-induced mucositis [9] . When all cycles were analyzed together, in monomicrobial BSIs, the proportion of gram-positive microorganisms was 43.2% and the proportion of gram-negatives was 37.9%. The corresponding figures in a recent study among patients with hematological malignancies and solid neoplasms in hospitals in the USA with neutrophil counts of less than 1,000/µL were 61 and 24.9%, respectively [8] . In our series, from cycles I to IV, the numbers of gram-positives decreased (from 71.7 to 36.6%) and the numbers of gramnegatives increased (from 21.7 to 46.9%). The great proportion of gram-negatives in cycles III and IV was unexpected, especially because severe gastrointestinal toxicity (WHO grades III and IV) decreased from cycle to cycle. E. coli and Klebsiella species were the most commonly yielded gram-negatives, as has been shown in several previous series.
Of the gram-positive microorganisms, CoNS were the most common finding in our series in general or in the four different cycles. During the last few decades, much attention has been paid to the importance of viridans group streptococci as a cause of BSIs during neutropenia. In several studies, it has been associated with high-dose cytarabine chemotherapy [30] [31] [32] and quinolone prophylaxis [7] . In our study, the incidence of BSIs caused by viridans group streptococci was highest during the second cycle with high-dose cytarabine and idarubicin, and was clearly lower in cycle IV, which also included high-dose cytarabine and amsacrine. Thus, the combination of chemotherapeutics and not only the high-dose cytarabine per se seems to be important for BSIs caused by viridans group streptococci.
It has been recently noted that the knowledge of polymicrobial infections among cancer patients is sparse [33] . In trials involving neutropenic patients, the proportion of polymicrobial BSIs has varied from 8 to 32% [34, 35] . Our overall figure of polymicrobial BSIs was 28.3%. However, there was, once again, substantial inter-cycle variation. In three-fourths of the episodes, polymicrobial BSIs were caused by two microorganisms. The most common combination included both gram-positive and gram-negative microorganisms and the second most common included at least two gram-positive microorganisms together.
When polymicrobial BSIs were also taken into account in our study, which included the series of AML patients recruited between 1992 and 2001, the portion of grampositive microorganisms in BSIs was even higher (79.6%) than in the previously mentioned study from the USA: their highest figure (76%) was from the year 2000 [8] . The result of 50.9% gram-negative organisms when polymicrobial BSIs were also included is quite similar to a recent study [36] , where patients were also treated without antibiotic prophylaxis. In another study, the proportion of gramnegatives was 52% without and 25% with antibiotic prophylaxis [23] .
In conclusion, our AML patients had a high overall BSI rate during chemotherapy regimen-induced neutropenia. However, there was great variation in BSI findings in four treatment cycles with different chemotherapeutics: the BSI rate was lowest in cycle I and the proportions of microorganisms and polymicrobial BSIs varied greatly from cycle to cycle. Therefore, in order to obtain more precise information concerning BSIs during the intensive chemotherapeutic treatments of AML, the analysis of BSI results should be focused on different chemotherapy cycles rather than by analyzing the overall results.
